Conduit Pharmaceuticals Inc. (NASDAQ:CDT - Get Free Report) saw a significant drop in short interest in the month of January. As of January 15th, there was short interest totalling 3,750,000 shares, a drop of 67.6% from the December 31st total of 11,570,000 shares. Based on an average daily volume of 52,100,000 shares, the days-to-cover ratio is presently 0.1 days.
Conduit Pharmaceuticals Stock Performance
NASDAQ:CDT traded down $0.23 during midday trading on Tuesday, reaching $3.07. The stock had a trading volume of 4,665,933 shares, compared to its average volume of 1,508,507. The firm's fifty day simple moving average is $8.03 and its 200-day simple moving average is $12.25. Conduit Pharmaceuticals has a 1-year low of $2.94 and a 1-year high of $392.00.
Conduit Pharmaceuticals Company Profile
(
Get Free Report)
Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Conduit Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Conduit Pharmaceuticals wasn't on the list.
While Conduit Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
